Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome Trial
Top Cited Papers
Open Access
- 28 March 2007
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 297 (12) , 1319-1331
- https://doi.org/10.1001/jama.297.12.1319
Abstract
During the past 2 decades, there have been substantial advances in drug therapy for chronic heart failure (HF), with much of the improvement in clinical outcomes achieved through pharmacologic inhibition of neurohormonal systems. Nevertheless, the number of annual hospitalizations for HF continues to rise, and mortality rates among patients hospitalized with HF remain high.1-7Keywords
This publication has 27 references indexed in Scilit:
- Congestion in Acute Heart Failure Syndromes: An Essential Target of Evaluation and TreatmentThe American Journal of Medicine, 2006
- Relation of Loop Diuretic Dose to Mortality in Advanced Heart FailurePublished by Elsevier ,2006
- EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of populationEuropean Heart Journal, 2006
- Nationwide survey on acute heart failure in cardiology ward services in ItalyEuropean Heart Journal, 2005
- Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)American Heart Journal, 2005
- The impact of arrhythmias in acute heart failureJournal of Cardiac Failure, 2004
- Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and designAmerican Heart Journal, 2004
- Relationship between heart failure treatment and development of worsening renal function among hospitalized patients1, *1American Heart Journal, 2004
- Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart FailureA Randomized Controlled TrialJAMA, 2002
- Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)American Heart Journal, 1999